Metformin, Careprost, Sildenafil, Tadalafil

All product prices are in US dollars.
US Brand Name Generic Sandostatin
Generic Name Somatostatin
Other Brand Name Somastat
Packing 2
Manufacturer Sun Pharma
Form Injection
Strength 3mg
Country India

  • 1 ampoule 3mg $132.28
Available online
More Views



This product of Sun Pharma available in both depot and immediate release form is a breakthrough in the treatment of acromegaly in patients who have failed previous treatment or are the candidates of surgery or radiation therapy. The product is meant for the patients who have responded or tolerated well to the octreotide-immediate release injection. The product can also be indicated in the use of the metastatic carcinoid tumors and vasoactive intestinal peptide tumors.


The product is used in conditions like clinically diagnosed acromegaly and in patients who are the candidates for surgery and on those undergoing radiation therapies. The drug is also used in those who have tolerated well to octeotide immediate release injections.

Side effects

Hypersensitivity is the most common side effect encountered in the use of the drug. It may induce other side effects like nausea, vomiting and abdominal discomfort in some individual. The drug may induce pain and inflammation at the site of the injection. Intolerant subjects may suffer severe diarrhea or GI upset and rashes following the administration of the drug.


The drug is contraindicated for patients who are hypersensitive to octreotide or any other components of the suspension. The product should not be used in patients suffering from diabetes, gall bladder impairment or malnutrition.


The drug should be stored in a refrigerator at a temperature from 2 to 8 degree Celsius. The product should be warmed at room temperature for 30 minutes before injection. The kit must be reconstituted and administered by healthcare professionals.


The immediate release injection is available in 0.05 mg/mL, 0.1 mg/mL, 0.2 mg/mL, 0.5 mg/mL, 1 mg/mL injection solutions. The depot forms contain kits for reconstitution containing extended release biodegradable polymer microspheres: 10mg, 20mg, and 30mg. The product contains the active substance octreotide free peptide, 10mg, 20mg or 40 mg nominally 4.15% of fill weight equivalent to 4.65% of octreotide acetate. Also contains polylactide and mannitol.

Important Precautions

Patients using the drug should be closely monitored for the bradycardia. The drug should be cautiously used in hypothyroidism as it can aggravate the condition. It should be cautiously used in diabetics and gall bladder impairment as it may cause cholelithiasis.

Dosage and administration

The immediate release injection is initiated at 50 mcg TID and is subsequently increased to 100 to 500 mcg TID as needed to control growth hormone and insulin as like growth factor 1 levels. Most patients are controlled on 100 mcg TID. The drug is continued for at least 2 weeks to determine tolerance before converting to depot octreotide injection. It may be given subcutaneously or intravenously. The depot injection therapy is initiated with 20 mg deep gluteal IM injection every 4 weeks for 3 doses, and then the dose is adjusted based on patients' GH and IGF1 levels. At 3 months, adjust as follows: GH Greater than 2.5 ng/mL, IGF1 elevated, and/or clinical symptoms are uncontrolled: 30 mg every 4 weeks. GH Greater than 1 to less than equal to 2.5 ng/mL, IGF1 normal and clinical symptom is controlled: 20 mg every 4 weeks. GH greater than 1 ng/mL, IGF1 normal and clinical symptoms are controlled: 10 mg every 4 weeks. For immediate release injections the drug should be given for at least 2 weeks in order to monitor the response and tolerance. Then the dosage may be converted into a long term depot injection.